局部晚期宫颈癌新辅助化疗近期疗效观察

Survey on Recent Effect of Neoadjuvant Chemotherapy of Locally Advanced Cervical Carcinoma

目的探讨紫杉醇联合铂类新辅助化疗对局部晚期宫颈癌治疗的近期疗效。方法对46例局部晚期宫颈癌的病人用紫杉醇联合顺铂（或卡铂）行1～2个疗程的新辅助化疗，观察近期疗效。结果新辅助化疗近期临床总有效率（CR＋PR）848％，手术切除率为100％，手术切除标本切缘均为阴性。结论紫杉醇联合顺铂（或卡铂）对局部晚期宫颈癌行新辅助化疗可明显缩小瘤体，提高手术的切净率，减少不良预后因素。

In this paper authors want to probe the recent effect of neoadjuvant chemotherapy of paclitaxel plus platinum in locally advanced cervical carcinoma. Observe the recent effect through using paclitaxel and cesplatin to 46 patients who suffered locally advanced cervical carcinoma to implement 1 to 2 treatment of courses＇ neoadjuvant chemotherapy. And the result is that the recent clinical total efficient （CR＋PR） is 84.8%, and the resetting rate is 100%. The specimens＇ cutting edges are all negative. So the authors can draw the conclusion that using paclitaxel and cesplatin to the locally advanced cervical carcinoma patients to implement neoadjuvant chemotherapy can obviously shrink tumors, improve the rate of complete resection, and it also can reduce the negative factors after recovery.